NKGen Biotech（NKGN）株式概要NKGen Biotech, Inc.は臨床段階のバイオテクノロジー企業として、自己、同種、CAR-NKナチュラルキラー細胞療法の開発と商業化に注力している。 詳細NKGN ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ マイナスの株主資本 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )+1 さらなるリスクすべてのリスクチェックを見るNKGN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.06該当なし内在価値ディスカウントEst. Revenue$PastFuture-80m340k2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesGANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.1% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2225428d agoNKGen Biotech, Inc. 競合他社MetaViaSymbol: NasdaqCM:MTVAMarket cap: US$7.7mTransCode TherapeuticsSymbol: NasdaqCM:RNAZMarket cap: US$7.7mSilo PharmaSymbol: NasdaqCM:SILOMarket cap: US$7.3mPharmaCyte BiotechSymbol: NasdaqCM:PMCBMarket cap: US$8.1m価格と性能株価の高値、安値、推移の概要NKGen Biotech過去の株価現在の株価US$0.0652週高値US$0.4652週安値US$0.0002ベータ0.811ヶ月の変化0%3ヶ月変化0%1年変化-52.79%3年間の変化-99.41%5年間の変化n/aIPOからの変化-99.38%最新ニュースNKGen Biotech, Inc. Presents Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal DementiaApr 10Nkgen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’S DiseaseMar 23NKGen Biotech, Inc. Appoints Bruce L. Miller to Scientific Advisory BoardJan 22NKGen Biotech, Inc. to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy ForumSep 18NKGen Biotech, Inc. Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025Jul 29Nkgen Biotech, Inc. Receives Fda Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJul 21最新情報をもっと見るRecent updatesNKGen Biotech, Inc. Presents Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal DementiaApr 10Nkgen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’S DiseaseMar 23NKGen Biotech, Inc. Appoints Bruce L. Miller to Scientific Advisory BoardJan 22NKGen Biotech, Inc. to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy ForumSep 18NKGen Biotech, Inc. Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025Jul 29Nkgen Biotech, Inc. Receives Fda Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJul 21The Nasdaq Stock Market to Delist the Common Stock of NKGen BiotechJul 14Nkgen Biotech, Inc. Announces the Administration of the First Dose of TroculeucelJul 11Nkgen Biotech Announces International and U.S. Expansion of Phase 1/2A Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and FloridaJun 24NKGen Biotech, Inc. announced delayed 10-Q filingMay 16NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)Apr 07NKGen Biotech, Inc. announced delayed annual 10-K filingApr 01NKGen Biotech, Inc. announced that it has received $5 million in fundingMar 11NKGen Biotech, Inc.(OTCPK:NKGN) dropped from S&P TMI IndexMar 07NKGen Biotech, Inc.(OTCPK:NKGN) dropped from NASDAQ Composite IndexMar 05+ 1 more updateNKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use ProgramMar 03NKGen Biotech, Inc. Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFeb 21NKGen Biotech, Inc. Appoints Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast SiteFeb 20NKGen Biotech, Inc. Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's DiseaseFeb 14NKGen Biotech, Inc. Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's DiseaseFeb 13NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings PanelNov 27NKGen Biotech, Inc. announced delayed 10-Q filingNov 16NKGen Biotech Inc. Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease ConferenceOct 30The Nasdaq Stock Market Notifies NKGen Biotech That it Withdraws the Staff Deficiency LetterOct 25NKGen Biotech, Inc. Announces Board and Committee ElectionsOct 04NKGen Biotech Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price RequirementSep 28NKGen Biotech Provides Compliance Update with Nasdaq Listing RulesSep 19NKGen Biotech, Inc. Announces Pierre Gagnon as Chief Operating Officer and as an Officer of the CompanyAug 24NKGen Biotech Receives Notification from Nasdaq Related to Delayed Quarterly ReportAug 23NKGen Biotech, Inc. announced delayed 10-Q filingAug 15NKGen Biotech, Inc Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International ConferenceAug 01NKGen Biotech, Inc., Annual General Meeting, Aug 28, 2024Jul 24NKGen Biotech, Inc. Elects Dr. Marco Gottardis as Class I Director, Audit Committee, Compensation Committee and N&Cg CommitteeJul 12NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024Jun 05NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25NKGen Biotech, Inc.’s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 23NKGen Biotech, Inc. announced delayed 10-Q filingMay 17NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LPApr 30+ 1 more updateNKGen Biotech, Inc. announced delayed annual 10-K filingApr 03NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease At the Tau2024 Global ConferenceMar 26NKGen Biotech Receives Non-Compliance Notice from Nasdaq Regarding Market Value of Listed Securities RequirementMar 18New major risk - Share price stability Mar 07NKGen Biotech Receives a Written Notice from the Nasdaq Stock MarketFeb 21NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance CommitteeFeb 10High number of new and inexperienced directors Dec 31NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's DiseaseDec 29NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's DiseaseDec 27Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOct 27NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's DiseaseOct 25No independent directors Oct 06株主還元NKGNUS BiotechsUS 市場7D0%-2.2%0.6%1Y-52.8%30.4%28.7%株主還元を見る業界別リターン: NKGN過去 1 年間で30.4 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: NKGNは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is NKGN's price volatile compared to industry and market?NKGN volatilityNKGN Average Weekly Movement140.3%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.3%安定した株価: NKGNの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: NKGNの 週次ボラティリティ は、過去 1 年間で100%から140%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201726Paul Y. Songnkgenbiotech.comNKGen Biotech, Inc.は臨床段階のバイオテクノロジー企業として、自己、同種、CAR-NKナチュラルキラー細胞療法の開発と商業化に注力している。同社の主力製品には、神経変性疾患の治療薬候補である自己NK細胞療法SNK01と、難治性固形がんを対象とした臨床第1相試験中の同種NK細胞療法SNK02がある。同社はNKMAX社とライセンス契約を結んでいる。以前はNKMAX America, Inc.として知られていた。NKGen Biotech, Inc.は2017年に設立され、カリフォルニア州サンタアナに本社を置いている。もっと見るNKGen Biotech, Inc. 基礎のまとめNKGen Biotech の収益と売上を時価総額と比較するとどうか。NKGN 基礎統計学時価総額US$7.84m収益（TTM）-US$23.55m売上高(TTM)n/a0.0xP/Sレシオ-0.3xPER（株価収益率NKGN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NKGN 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$23.55m収益-US$23.55m直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.18グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-75.2%NKGN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 13:11終値2026/04/29 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NKGen Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
GANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.1% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2225428d ago
NKGen Biotech, Inc. Presents Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal DementiaApr 10
Nkgen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’S DiseaseMar 23
NKGen Biotech, Inc. to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy ForumSep 18
NKGen Biotech, Inc. Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025Jul 29
Nkgen Biotech, Inc. Receives Fda Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJul 21
NKGen Biotech, Inc. Presents Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal DementiaApr 10
Nkgen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’S DiseaseMar 23
NKGen Biotech, Inc. to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy ForumSep 18
NKGen Biotech, Inc. Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025Jul 29
Nkgen Biotech, Inc. Receives Fda Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJul 21
Nkgen Biotech Announces International and U.S. Expansion of Phase 1/2A Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and FloridaJun 24
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)Apr 07
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use ProgramMar 03
NKGen Biotech, Inc. Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFeb 21
NKGen Biotech, Inc. Appoints Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast SiteFeb 20
NKGen Biotech, Inc. Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's DiseaseFeb 14
NKGen Biotech, Inc. Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's DiseaseFeb 13
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings PanelNov 27
NKGen Biotech Inc. Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease ConferenceOct 30
NKGen Biotech Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price RequirementSep 28
NKGen Biotech, Inc. Announces Pierre Gagnon as Chief Operating Officer and as an Officer of the CompanyAug 24
NKGen Biotech, Inc Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International ConferenceAug 01
NKGen Biotech, Inc. Elects Dr. Marco Gottardis as Class I Director, Audit Committee, Compensation Committee and N&Cg CommitteeJul 12
NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024Jun 05
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25
NKGen Biotech, Inc.’s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 23
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LPApr 30+ 1 more update
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease At the Tau2024 Global ConferenceMar 26
NKGen Biotech Receives Non-Compliance Notice from Nasdaq Regarding Market Value of Listed Securities RequirementMar 18
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance CommitteeFeb 10
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's DiseaseDec 29
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's DiseaseDec 27
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOct 27
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's DiseaseOct 25
